Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers

The PROSE Study Group

Timothy R. Rebbeck, Tara Friebel, Theresa Wagner, Henry T. Lynch, Judy E. Garber, Mary B. Daly, Claudine Isaacs, Olufunmilayo I. Olopade, Susan L. Neuhausen, Laura Van't Veer, Rosalind Eeles, D. Gareth Evans, Gail Tomlinson, Ellen Matloff, Steven A. Narod, Andrea Eisen, Susan Domchek, Katrina Armstrong, Barbara L. Weber

Research output: Contribution to journalArticle

292 Citations (Scopus)

Abstract

Purpose: Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal women choose to take hormone replacement therapy (HRT) after undergoing BPO to abrogate immediate symptoms of surgically-induced menopause. Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT. Methods: We identified a prospective cohort of 462 women with disease-associated germline BRCA1/2 mutations at 13 medical centers to evaluate breast cancer risk after BPO with and without HRT. We determined the incidence of breast cancer in 155 women who had undergone BPO and in 307 women who had not undergone BPO on whom we had complete information on HRT use. Postoperative follow-up was 3.6 years. Results: Consistent with previous reports, BPO was significantly associated with breast cancer risk reduction overall (hazard ratio [HR] = 0.40; 95% CI, 0.18 to 0.92). Using mutation carriers without BPO or HRT as the referent group, HRT of any type after BPO did not significantly alter the reduction in breast cancer risk associated with BPO (HR = 0.37; 95% CI, 0.14 to 0.96). Conclusion: Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA 1/2 mutation carriers.

Original languageEnglish
Pages (from-to)7804-7810
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number31
DOIs
StatePublished - 2005

Fingerprint

Hormone Replacement Therapy
Ovariectomy
Risk Reduction Behavior
Breast Neoplasms
Mutation
Menopause

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers : The PROSE Study Group. / Rebbeck, Timothy R.; Friebel, Tara; Wagner, Theresa; Lynch, Henry T.; Garber, Judy E.; Daly, Mary B.; Isaacs, Claudine; Olopade, Olufunmilayo I.; Neuhausen, Susan L.; Van't Veer, Laura; Eeles, Rosalind; Evans, D. Gareth; Tomlinson, Gail; Matloff, Ellen; Narod, Steven A.; Eisen, Andrea; Domchek, Susan; Armstrong, Katrina; Weber, Barbara L.

In: Journal of Clinical Oncology, Vol. 23, No. 31, 2005, p. 7804-7810.

Research output: Contribution to journalArticle

Rebbeck, TR, Friebel, T, Wagner, T, Lynch, HT, Garber, JE, Daly, MB, Isaacs, C, Olopade, OI, Neuhausen, SL, Van't Veer, L, Eeles, R, Evans, DG, Tomlinson, G, Matloff, E, Narod, SA, Eisen, A, Domchek, S, Armstrong, K & Weber, BL 2005, 'Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group', Journal of Clinical Oncology, vol. 23, no. 31, pp. 7804-7810. https://doi.org/10.1200/JCO.2004.00.8151
Rebbeck, Timothy R. ; Friebel, Tara ; Wagner, Theresa ; Lynch, Henry T. ; Garber, Judy E. ; Daly, Mary B. ; Isaacs, Claudine ; Olopade, Olufunmilayo I. ; Neuhausen, Susan L. ; Van't Veer, Laura ; Eeles, Rosalind ; Evans, D. Gareth ; Tomlinson, Gail ; Matloff, Ellen ; Narod, Steven A. ; Eisen, Andrea ; Domchek, Susan ; Armstrong, Katrina ; Weber, Barbara L. / Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers : The PROSE Study Group. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 31. pp. 7804-7810.
@article{45088ca2f0124b6b86cde7d727b17196,
title = "Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group",
abstract = "Purpose: Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal women choose to take hormone replacement therapy (HRT) after undergoing BPO to abrogate immediate symptoms of surgically-induced menopause. Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT. Methods: We identified a prospective cohort of 462 women with disease-associated germline BRCA1/2 mutations at 13 medical centers to evaluate breast cancer risk after BPO with and without HRT. We determined the incidence of breast cancer in 155 women who had undergone BPO and in 307 women who had not undergone BPO on whom we had complete information on HRT use. Postoperative follow-up was 3.6 years. Results: Consistent with previous reports, BPO was significantly associated with breast cancer risk reduction overall (hazard ratio [HR] = 0.40; 95{\%} CI, 0.18 to 0.92). Using mutation carriers without BPO or HRT as the referent group, HRT of any type after BPO did not significantly alter the reduction in breast cancer risk associated with BPO (HR = 0.37; 95{\%} CI, 0.14 to 0.96). Conclusion: Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA 1/2 mutation carriers.",
author = "Rebbeck, {Timothy R.} and Tara Friebel and Theresa Wagner and Lynch, {Henry T.} and Garber, {Judy E.} and Daly, {Mary B.} and Claudine Isaacs and Olopade, {Olufunmilayo I.} and Neuhausen, {Susan L.} and {Van't Veer}, Laura and Rosalind Eeles and Evans, {D. Gareth} and Gail Tomlinson and Ellen Matloff and Narod, {Steven A.} and Andrea Eisen and Susan Domchek and Katrina Armstrong and Weber, {Barbara L.}",
year = "2005",
doi = "10.1200/JCO.2004.00.8151",
language = "English",
volume = "23",
pages = "7804--7810",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers

T2 - The PROSE Study Group

AU - Rebbeck, Timothy R.

AU - Friebel, Tara

AU - Wagner, Theresa

AU - Lynch, Henry T.

AU - Garber, Judy E.

AU - Daly, Mary B.

AU - Isaacs, Claudine

AU - Olopade, Olufunmilayo I.

AU - Neuhausen, Susan L.

AU - Van't Veer, Laura

AU - Eeles, Rosalind

AU - Evans, D. Gareth

AU - Tomlinson, Gail

AU - Matloff, Ellen

AU - Narod, Steven A.

AU - Eisen, Andrea

AU - Domchek, Susan

AU - Armstrong, Katrina

AU - Weber, Barbara L.

PY - 2005

Y1 - 2005

N2 - Purpose: Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal women choose to take hormone replacement therapy (HRT) after undergoing BPO to abrogate immediate symptoms of surgically-induced menopause. Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT. Methods: We identified a prospective cohort of 462 women with disease-associated germline BRCA1/2 mutations at 13 medical centers to evaluate breast cancer risk after BPO with and without HRT. We determined the incidence of breast cancer in 155 women who had undergone BPO and in 307 women who had not undergone BPO on whom we had complete information on HRT use. Postoperative follow-up was 3.6 years. Results: Consistent with previous reports, BPO was significantly associated with breast cancer risk reduction overall (hazard ratio [HR] = 0.40; 95% CI, 0.18 to 0.92). Using mutation carriers without BPO or HRT as the referent group, HRT of any type after BPO did not significantly alter the reduction in breast cancer risk associated with BPO (HR = 0.37; 95% CI, 0.14 to 0.96). Conclusion: Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA 1/2 mutation carriers.

AB - Purpose: Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal women choose to take hormone replacement therapy (HRT) after undergoing BPO to abrogate immediate symptoms of surgically-induced menopause. Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT. Methods: We identified a prospective cohort of 462 women with disease-associated germline BRCA1/2 mutations at 13 medical centers to evaluate breast cancer risk after BPO with and without HRT. We determined the incidence of breast cancer in 155 women who had undergone BPO and in 307 women who had not undergone BPO on whom we had complete information on HRT use. Postoperative follow-up was 3.6 years. Results: Consistent with previous reports, BPO was significantly associated with breast cancer risk reduction overall (hazard ratio [HR] = 0.40; 95% CI, 0.18 to 0.92). Using mutation carriers without BPO or HRT as the referent group, HRT of any type after BPO did not significantly alter the reduction in breast cancer risk associated with BPO (HR = 0.37; 95% CI, 0.14 to 0.96). Conclusion: Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA 1/2 mutation carriers.

UR - http://www.scopus.com/inward/record.url?scp=30944463691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944463691&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.00.8151

DO - 10.1200/JCO.2004.00.8151

M3 - Article

VL - 23

SP - 7804

EP - 7810

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -